Home | Life Sciences Intellectual Property Review
10 October 2024 Duo successfully invalidate two CureVac patents in the UK | High Court deems patents invalid due to lack of inventive step and insufficient technical contribution | CureVac “disappointed” but stressed outcome does not affect ongoing litigation in Germany and US. Roche to outside counsel: ‘Law firms must adapt to the modern ...
Latest News & Features | Life Sciences Intellectual Property Review
Oct 16, 2024 · How post-filing data rescued Novo Nordisk’s Ozempic patent in China. The Beijing IP court’s decision to revive a key semaglutide patent based on experimental data has far-reaching legal and economic implications, says Jennifer Che …
Unified Patent Court | Life Sciences Intellectual Property Review
Big Pharma. First few months of the Unified Patent Court: a review. Despite a rocky start, with case-management issues and plenty of scepticism from stakeholders, there is much to applaud in the UPC’s first four months, write Sebastian Moore and John Lao of Herbert Smith Freehills. Big Pharma. UPC: life sciences lead the momentum at new court.
Big Pharma counsel embrace AI but data and legal risks loom
6 hours ago · Counsel from Pfizer, Gilead, and Bristol Myers Squibb spoke on AI’s transformative power and risks, reports Marisa Woutersen at LSPN Fall North America.
Generics | Life Sciences Intellectual Property Review
All features. 2 April 2024 Teva and co-appellant Mylan gain second chance at launching generics of Invega Sustenna, owned by J&J subsidiary Janssen | US Court of Appeals vacates a lower court’s decision to grant validity to the drug’s last remaining patent. 28 March 2024 Judge disagrees that barrier against generic drug makers should be ...
CRISPR | Life Sciences Intellectual Property Review
9 November 2020 The European Patent Office has released the long-awaited reasoning for its decision to uphold the revocation of a Broad Institute CRISPR/Cas9 patent. In January this year, the EPO’s Board of Appeal concluded that the Broad’s patent, EP2,771,468, lacked novelty due to an invalid claim to priority.
The future of precision medicine part 1: challenges and …
Jun 13, 2018 · The promise of precision medicine has been extolled by researchers and clinicians for some time, but as sequencing costs continue to fall, sophistication of data analysis and patient stratification increases and data science and artificial intelligence (AI) begin to partner with the life sciences industry in earnest, that promise now seems closer than ever to realisation.
UPC: life sciences lead the momentum at new court
Aug 15, 2023 · 26 September 2023 An updated UPC rule requires a concrete and verifiable, legitimate reason for making available written pleadings and evidence | The wish from a natural person to form an opinion on the validity of a patent deemed insufficient reason for access | First decision marks latest twist in Amgen v Sanofi showdown.
Medtech | Life Sciences Intellectual Property Review
26 September 2024 Jennifer Godorn Wessman is leading efforts to protect the medtech company’s key assets. She sat down with LSIPR to discuss her team’s challenges, expanding into new markets, and why lawyers are salespeople too.
LSPN Fall: Why Big Pharma is facing 'a balancing act'
Oct 17, 2024 · For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at [email protected]